Decorin facilitates T cell-mediated antitumor immunity and augments the efficacy of anti-PD1 immunotherapy

Key Points

• Decorin significantly enhances T cell-mediated antitumor immunity, leading to improved therapeutic outcomes.
• A 40% increase in immune response was observed with decorin treatment alongside anti-PD1 therapy.
• Analysis conducted through in vivo models to assess immune response dynamics within the tumor microenvironment.
• Highlights potential of decorin as a crucial component in optimizing immunotherapy strategies.